CoChat

Novel views on new-onset diabetes after transplantation: development, prevention and treatment

Open access
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., Pacini, G., Port, F. K., Sharif, A., Saemann, M. D., European-New-Onset Diabetes After Transplantation Working Group · 2013 · Nephrology Dialysis Transplantation

The DOI matches its Crossref record; 183 of the 187 references it cites were found in a registry or an index.

Abstract

New-onset diabetes after transplantation (NODAT) is associated with increased risk of allograft failure, cardiovascular disease and mortality, and therefore, jeopardizes the success of renal transplantation. Increased awareness of NODAT and the prediabetic states (impaired fasting glucose and impaired glucose tolerance, IGT) has fostered previous and present recommendations, based on the management of type 2 diabetes mellitus (T2DM). Unfortunately, the idea that NODAT merely resembles T2DM is potentially misleading, because the opportunity to initiate adequate anti-hyperglycaemic treatment early after transplantation might be given away for 'tailored' immunosuppression in patients who have developed NODAT or carry personal risk factors. Risk factor-independent mechanisms, however, seem to render postoperative hyperglycaemia with subsequent development of overt or 'full-blown' NODAT, the unavoidable consequence of the transplant and immunosuppressive process itself, at least in many cases. A proof of the concept that timely preventive intervention with exogenous insulin against post-transplant hyperglycaemia may decrease NODAT was recently provided by a small clinical trial, which is awaiting confirmation from a multicentre study. However, because early insulin therapy aimed at beta-cell protection seems to contrast the currently recommended, stepwise approach of 'watchful waiting' prior to pancreatic decompensation, we here aim at reviewing recent concepts regarding the development, prevention and treatment of NODAT, some of which seem to challenge the traditional view on T2DM and NODAT. In summary, we suggest a novel, risk factor-independent management approach to NODAT, which includes glycaemic monitoring and anti-hyperglycaemic treatment in virtually everybody after transplantation. This approach has widespread implications for future research and is intended to tackle NODAT and also ultimately cardiovascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfs583

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 183 references

Research works printed but not linked: 4

  1. 1984, American Journal of Physiology - Gastrointestinal and Liver Physiology, 247, E592
  2. 1992, American Journal of Physiology - Gastrointestinal and Liver Physiology, 263, E663
  3. Cerasi E. β-Cell dysfunction vs insulin resistance in type 2 diabetes: the eternal ‘chicken and egg’ question. Medicographia N° 106. 2011;33:35–41. [Google Scholar]
  4. Sharif A. Metformin safety post-transplantation—trials and tribulations. Am J Transplant. 2012;12:796. [Google Scholar]

Cited by

Metadata

Authors
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., Pacini, G., Port, F. K., Sharif, A., Saemann, M. D., & European-New-Onset Diabetes After Transplantation Working Group
Affiliations
  • Medical University of Vienna (AT)
  • Hospital Del Mar (ES)
  • Charité – Universitätsmedizin Berlin (DE)
  • University of Michigan (US)
  • Universidad de La Laguna (ES)
  • National Research Council (IT)
  • Arbor Research Collaborative for Health (US)
  • Queen Elizabeth Hospital Birmingham (GB)
Corresponding author
Hecking, M.
Venue
Nephrology Dialysis Transplantation
Published
2013-01-17
Volume
28
Issue
3
Pages
550-566
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2164732183
Cited by
120
References
187
Citations by year
2026: 4 · 2025: 2 · 2024: 8 · 2023: 8 · 2022: 11 · 2021: 8 · 2020: 7 · 2019: 8 · 2018: 11 · 2017: 9 · 2016: 10 · 2015: 18 · 2014: 10 · 2013: 6
FWCI
10.71
Type
journal article
Language
en
Open access
Locations
  • Nephrology Dialysis Transplantation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (K24DK062234)
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
Keywords
post-transplant diabetes mellitus, kidney transplantation, type 2 diabetes, immunosuppression, impaired glucose tolerance, impaired fasting glucose, exogenous insulin therapy, beta-cell protection, glycaemic monitoring, allograft failure, cardiovascular disease
MeSH terms
Diabetes Mellitus, Type 2, Humans, Risk Factors, Organ Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.